HCPs Pre-Congress & Symposia Survey + Evaluation Form (EUSTM-2023)

Health Care Professionals (HCPs) Attendees: Please complete the following pre-activity survey and evaluation questions so we can review our events goals, objectives, and topics.

Question Title

* 1. Please provide the following information:

Name & Credentials

Specialty

City/Town

Country

Email Address

Question Title

* 2. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #1: “Describe clinical trials (both complete and ongoing) on the application of ADCs in the treatment of mUC patients”

Expert

Need more proficiency

Need more knowledge

None

Question Title

* 3. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #2: “Explain the rationale of ADC use in mUC alone and in combination with immunotherapeutics”:

Expert

Need more proficiency

Need more knowledge

None

Question Title

* 4. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #3: “Recount emerging efficacy and safety data of ADCs in the treatment of mUC patients”:

Expert

Need more proficiency

Need more knowledge

None

Question Title

* 5. Sacituzumab Govitecan is an Antibody Drug Conjugate that targets...

Nectin-4

Trop-2

Her-2

KRAS

PSMA

Question Title

* 6. A 72 years-old male with metastatic urothelial carcinoma, treated with 4 cycles of cisplatin and gemcitabine, CT scan suggested a very good response. How would you manage this patient?

Avelumab

Sacituzumab

Enfortumab

Trastuzumab

Erdafetinib

Question Title

* 7. A 65 years-old female with poorly controlled diabetes, now with muscle-invasive bladder carcinoma with metastasis to the liver disease, progressed after chemo with carboplatin, gemcitabine and pembrolizumab. NGS no target mutation. How would you treat next?

Avelumab

Enfortumab

Sacituzumab

Trastuzumab

Erdafetinib

Question Title

* 8. A 66-year-old male patient is diagnosed with mUC, he has an ECOG 1, labs are unremarkable except for a GFR of 52, and he has no grade 3 sequelae from his treatment. He has previously received carboplatin with gemcitabine during neoadjuvant therapy, pembrolizumab, and enfortumab vedotin for advanced disease—which of the following statements is true?

Disitamab vedotin is approved as standard of care for this patient

There is a >80% chance of detecting HER2 expression in this patient's
tumor

This patient should be screened for a HER2-directed ADC trial

Supportive care is the next best step for this patient

Question Title

* 9. A 72-year-old male patient with refractory mUC is enrolled in a clinical study of the Her2-directed antibody trastuzumab deruxtecan. Initial treatment is uneventful, but three months into treatment, the patient presents to the ER with worsening exertional dyspnea and cough. Which of the following is likely to be the drug-associated adverse event to explain his presentation?

Pulmonary Embolism

Interstitial Lung Disease

Pneumonia

Churg Strauss Syndrome

DRESS syndrome

Question Title

* 10. Which of the following statements is true?

HER2 is an intracytoplasmic nuclear factor involved in proliferation and
angiogenesis.

IHC staining is necessary and sufficient as a predictor of ADC activity in HER2
expressing tumors.

High expression of HER2 is associated with increased toxicity from targeted ADCs.

HER2 is a transmembrane tyrosine kinase receptor.

Question Title

* 11. A 65 years-old woman received gemcitabine and cisplatin for metastatic UC, had a partial response after 6 cycles, developed grade 1 peripheral neuropathy, received avelumab, had PD after 3 cycles, was started on enfortumab vedotin (EV) 1.25 mg/kg day 1, 8, 15 q28days, developed grade 2 peripheral neuropathy after 3 cycles.

What will you do next?

Continue EV at 1.25 mg/kg

Continue EV at reduced dose 1 mg/kg

WITHHOLD EV until neuropathy improves to grade 1 then resume EV
at lower dose 1 mg/kg

Question Title

* 12. A 70 years-old man on EV 1.25 mg/kg develops a generalized maculopapular rash over trunk, back and extremities, itchy
What will you do?

Continue EV at current dose

Continue EV at reduced dose

WITHHOLD EV, prescribe topical steroids and antihistamine, refer
to Dermatology and do not resume EV until rash resolves to
grade 1 or less

Question Title

* 13. A 73 years-old man on EV 1.25 mg/kg, BMI 35 has blood glucose level of 320 mg/dL on the day of EV treatment

What will you do?

Continue EV at current dose and monitor BS

Continue EV at reduced dose and monitor BS

WITHHOLD EV, check HbA1C, refer to endocrinology for BS
management, resume EV once BS well controlled

HCPs Pre-Congress & Symposia Survey + Evaluation Form (EUSTM-2023)

Question Title

* 1. Please provide the following information:

Question Title

* 2. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #1: “Describe clinical trials (both complete and ongoing) on the application of ADCs in the treatment of mUC patients”

Question Title

* 3. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #2: “Explain the rationale of ADC use in mUC alone and in combination with immunotherapeutics”:

Question Title

* 4. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #3: “Recount emerging efficacy and safety data of ADCs in the treatment of mUC patients”:

Question Title

* 5. Sacituzumab Govitecan is an Antibody Drug Conjugate that targets...

Question Title

* 6. A 72 years-old male with metastatic urothelial carcinoma, treated with 4 cycles of cisplatin and gemcitabine, CT scan suggested a very good response. How would you manage this patient?

Question Title

* 7. A 65 years-old female with poorly controlled diabetes, now with muscle-invasive bladder carcinoma with metastasis to the liver disease, progressed after chemo with carboplatin, gemcitabine and pembrolizumab. NGS no target mutation. How would you treat next?

Question Title

Question Title

Question Title

* 10. Which of the following statements is true?

Question Title

Question Title

* 12. A 70 years-old man on EV 1.25 mg/kg develops a generalized maculopapular rash over trunk, back and extremities, itchyWhat will you do?

Question Title

* 13. A 73 years-old man on EV 1.25 mg/kg, BMI 35 has blood glucose level of 320 mg/dL on the day of EV treatmentWhat will you do?

* 12. A 70 years-old man on EV 1.25 mg/kg develops a generalized maculopapular rash over trunk, back and extremities, itchy
What will you do?

* 13. A 73 years-old man on EV 1.25 mg/kg, BMI 35 has blood glucose level of 320 mg/dL on the day of EV treatment

What will you do?